381 related articles for article (PubMed ID: 26433592)
1. Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development.
Garcia-Carbonero R; Garcia-Figueiras R; Carmona-Bayonas A; Sevilla I; Teule A; Quindos M; Grande E; Capdevila J; Aller J; Arbizu J; Jimenez-Fonseca P;
Cancer Metastasis Rev; 2015 Dec; 34(4):823-42. PubMed ID: 26433592
[TBL] [Abstract][Full Text] [Related]
2. Endoscopic imaging in the management of gastroenteropancreatic neuroendocrine tumors.
Pellicano R; Fagoonee S; Altruda F; Bruno M; Saracco GM; De Angelis C
Minerva Endocrinol; 2016 Dec; 41(4):490-8. PubMed ID: 27600643
[TBL] [Abstract][Full Text] [Related]
3. Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions.
Deroose CM; Hindié E; Kebebew E; Goichot B; Pacak K; Taïeb D; Imperiale A
J Nucl Med; 2016 Dec; 57(12):1949-1956. PubMed ID: 27811124
[TBL] [Abstract][Full Text] [Related]
4. Hegemony and cost-effectiveness of endoscopic ultrasound (EUS) in the field of gastroenteropancreatic-neuroendocrine tumors (GEP-NETs).
De Angelis C; Manfrè SF; Bruno M; Pellicano R
Minerva Med; 2014 Oct; 105(5):363-70. PubMed ID: 25325565
[TBL] [Abstract][Full Text] [Related]
5. New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors.
Phan AT; Kunz PL; Reidy-Lagunes DL
Clin Adv Hematol Oncol; 2015 May; 13(5 Suppl 5):1-18; quiz 1 p following 18. PubMed ID: 26430956
[TBL] [Abstract][Full Text] [Related]
6. Gastroenteropancreatic neuroendocrine tumours (GEP-NET) - Imaging and staging.
Baumann T; Rottenburger C; Nicolas G; Wild D
Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):45-57. PubMed ID: 26971843
[TBL] [Abstract][Full Text] [Related]
7. Current status of Interventional Radiology in the management of Gastro-Entero-Pancreatic Neuroendocrine Tumours (GEP-NETs).
Orgera G; Krokidis M; Cappucci M; Gourtsoyianni S; Tipaldi MA; Hatzidakis A; Rebonato A; Rossi M
Cardiovasc Intervent Radiol; 2015 Feb; 38(1):13-24. PubMed ID: 25366087
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Gastroenteropancreatic Neuroendocrine Tumors.
Perez K; Chan J
Surg Pathol Clin; 2019 Dec; 12(4):1045-1053. PubMed ID: 31672293
[TBL] [Abstract][Full Text] [Related]
9. An update on gastroenteropancreatic neuroendocrine tumors.
Cives M; Strosberg J
Oncology (Williston Park); 2014 Sep; 28(9):749-56, 758. PubMed ID: 25224471
[TBL] [Abstract][Full Text] [Related]
10. Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors.
Jiménez-Fonseca P; Carmona-Bayonas A; Martín-Pérez E; Crespo G; Serrano R; Llanos M; Villabona C; García-Carbonero R; Aller J; Capdevila J; Grande E;
Cancer Metastasis Rev; 2015 Sep; 34(3):381-400. PubMed ID: 26245646
[TBL] [Abstract][Full Text] [Related]
11. The emerging role of targeted therapies for advanced well-differentiated gastroenteropancreatic neuroendocrine tumors.
Cloyd JM; Konda B; Shah MH; Pawlik TM
Expert Rev Clin Pharmacol; 2019 Feb; 12(2):101-108. PubMed ID: 30582383
[TBL] [Abstract][Full Text] [Related]
12. New and emerging systemic therapy options for well-differentiated gastroenteropancreatic neuroendocrine tumors.
Scoville SD; Cloyd JM; Pawlik TM
Expert Opin Pharmacother; 2020 Feb; 21(2):183-191. PubMed ID: 31760823
[No Abstract] [Full Text] [Related]
13. Gastroenteropancreatic Neuroendocrine Tumors.
Cives M; Strosberg JR
CA Cancer J Clin; 2018 Nov; 68(6):471-487. PubMed ID: 30295930
[TBL] [Abstract][Full Text] [Related]
14. Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important.
Jin XF; Spampatti MP; Spitzweg C; Auernhammer CJ
Rev Endocr Metab Disord; 2018 Jun; 19(2):145-158. PubMed ID: 29464446
[TBL] [Abstract][Full Text] [Related]
15. Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials.
Cives M; Soares HP; Strosberg J
Curr Opin Oncol; 2016 Jul; 28(4):359-66. PubMed ID: 27138571
[TBL] [Abstract][Full Text] [Related]
16. Consensus document on the progression and treatment response criteria in gastroenteropancreatic neuroendocrine tumors.
Merino-Casabiel X; Aller J; Arbizu J; García-Figueiras R; González C; Grande E; Jiménez-Fonseca P; Sevilla MI; Capdevila J
Clin Transl Oncol; 2018 Dec; 20(12):1522-1528. PubMed ID: 29766455
[TBL] [Abstract][Full Text] [Related]
17. Gastroenteropancreatic neuroendocrine neoplasms: genes, therapies and models.
Kawasaki K; Fujii M; Sato T
Dis Model Mech; 2018 Feb; 11(2):. PubMed ID: 29590641
[TBL] [Abstract][Full Text] [Related]
18. SNM 2012 image of the year.
J Nucl Med; 2012 Oct; 53(10):23N. PubMed ID: 23028181
[No Abstract] [Full Text] [Related]
19. Treatment Strategies for Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract.
Cives M; Strosberg J
Curr Treat Options Oncol; 2017 Mar; 18(3):14. PubMed ID: 28286921
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapies for well-differentiated grade 3 gastroenteropancreatic neuroendocrine tumors: A new category in the World Health Organization classification.
Xu JX; Wu DH; Ying LW; Hu HG
World J Gastroenterol; 2021 Dec; 27(47):8123-8137. PubMed ID: 35068858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
